转移性结直肠癌患者总生存期的相关新基因APOH、KNG1和FGG

Identification of novel genes correlated with overall survival of patients with metastatic colorectal cancer:APOH,KNG1,and FGG

目的 通过生物信息学方法探讨结直肠癌转移的分子机制,为结直肠癌转移提供潜在的治疗靶点。方法 从高通量基因表达数据库(GEO)下载GSE41568数据集,用Limma软件包筛选转移性和原发性结直肠癌的差异表达基因;通过加权基因共表达网络分析(WGCNA)筛选与结直肠癌不同转移部位相关的核心模块和核心基因;使用STRING和Cytoscape构建蛋白质-蛋白质相互作用(PPI)网络;利用PROGgenesV2数据库进行预后分析。通过基因集富集分析(GSEA)预测基因参与结直肠癌的潜在分子机制。结果 共获得1 159个差异表达基因,由703个上调基因和456个下调基因组成。共表达模块中,前50个核心基因的基因本体(GO)功能富集分析表明,基因主要与创伤反应和急性炎症反应相关。通过PPI网络筛选的3个核心基因APOH、KNG1和FGG对结直肠癌患者的预后有显著影响。结论 APOH、KNG1和FGG与结直肠癌患者的预后呈负相关,这些基因有望成为结直肠癌的诊断生物标志物或治疗靶点。

Objective To explore the molecular mechanisms of colorectal cancer metastasis by bioinformatical methods and provide potential therapeutic targets for metastatic colorectal cancer.Methods The GSE41568 dataset was downloaded from the Gene Expression Omnibus database,and differentially expressed genes(DEGs)between metastatic and primary colorectal cancer were screened by the Limma software package in R.The network-centric modules and genes associated with different metastatic sites of colorectal cancer were then identified by weighted gene co-expression network analysis.Additionally,the protein-protein interaction network was predicted using the STRING database and visualized with Cytoscape software.Furthermore,the prognosis of patients with colorectal cancer was predicted using the PROGgenesV2 database.Finally,the potential molecular mechanisms of the genes were predicted by gene set enrichment analysis.Results A total of 1159 DEGs,including 703 upregulated and 456 downregulated,were obtained in this study.In the co-expression analysis,50 top hub genes from the turquoise modules were chosen for gene ontology functional enrichment analysis,which indicated that these genes were mainly associated with a response to wounding and an acute inflammatory response.Conclusion APOH,KNG1,and FGG were predicted to be negatively correlated with the prognosis of patients with colorectal cancer,indicating that they could serve as potential diagnostic biomarkers or therapeutic targets in patients with colorectal cancer.